Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, and Puma Biotechnology.

Community Practice Connections™: Navigating Treatment Options for HER2+ Breast Cancer Across the Disease Continuum: An Expert Tumor Board Discussion

Release Date: January 31, 2021
Expiration Date: January 31, 2022

Activity Overview

For patients with both early-stage and advanced/metastatic HER2+ breast cancer, treatment with HER2-targeted therapies has been shown to improve both short- and long-term survival. Over the past few years, results from pivotal trials and new regulatory approvals have expanded therapeutic options. Treatment paradigms are rapidly evolving in both (neo)adjuvant and metastatic settings. Several promising new HER2-targeted agents are in late-phase clinical trials, providing additional options for patients with relapsed/refractory disease.

This Community Practice Connections™ program provides an in-depth review of several key highlights from the Navigating Treatment Options for HER2+ Breast Cancer Across the Disease Continuum: An Expert Tumor Board Discussion satellite symposium, held in December 2020. This unique and engaging multimedia activity is directed toward the community-based clinician and focuses on the practical aspects of managing patients with HER2+ breast cancer, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, and Puma Biotechnology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists. Surgical oncologists, pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the management of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Incorporate emerging clinical evidence for HER2-targeted agents into individualized treatment plans for patients with early-stage or advanced/metastatic HER2+ breast cancer
  • Review current treatment standards and emerging options for patients with HER2+ breast cancer with brain metastases
  • Consider ongoing clinical trials of investigational agents for HER2+ breast cancer and the potential effect of emerging data on current treatment algorithms
  • Implement effective strategies for preventing or managing treatment-related adverse events in patients receiving HER2-targeted therapy for breast cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Joyce O'Shaughnessy, MD
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
Chair, Breast Cancer Research Program
The US Oncology Network
Dallas, TX

Disclosures: Consultant: Novartis, AstraZeneca, Celgene, Lilly, Merck, Pfizer, Seagen.

Mark D. Pegram, MD
Mark D. Pegram, MD
Director, Breast Cancer Oncology Program
Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology
Stanford University School of Medicine
Stanford Cancer Institute
Stanford, CA

Disclosures: Consultant: Roche/Genentech, Seagen, Daiichi Sankyo/AstraZeneca; Other: Lilly (spouse).

Hope S. Rugo, MD, FASCO
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant Research Support: Pfizer, Merck, Novartis, Lilly, Genentech, OBI Pharma, Odonate Therapeutics, Daiichi Sankyo, Eisai, Seagen, MacroGenics, Sermonix Pharmaceuticals, Immunomedics; Consultant: Samsung, Puma Biotechnology (limited consulting); Other: Travel: Daiichi Sankyo, Mylan, Pfizer, Merck, AstraZeneca, Novartis, MacroGenics.

Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Associate Director, Susan F. Smith Center for Women's Cancers
Director, Clinical Trials, Breast Oncology
Director, Breast Immunotherapy Clinical Research
Senior Physician
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant Research Support: Genentech, Lilly, Novartis, AstraZeneca, Merck, Pfizer, Nektar Therapeutics, Exelixis, Bristol Myers Squibb, Eisai, Cyclacel Pharmaceuticals, Immunomedics, Odonate Therapeutics, Seagen; Consultant: Puma Biotechnology, Nektar Therapeutics, Merck, AstraZeneca, Daiichi Sankyo, NanoString Technologies, Lilly, Pfizer, Novartis, Eisai, Genentech, Immunomedics, Sanofi, Celldex Therapeutics, Paxman, Seagen, Odonate Therapeutics, Bristol Myers Squibb, G1 Therapeutics, Silverback Therapeutics, AbbVie, Athenex, OncoPep, Samsung Bioepis, Kyowa Kirin, CytomX Therapeutics.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By